Baseline hormone levels in randomized participants with and without COVID-19 and overall
| . | Testosterone arm (n = 2601) . | Placebo arm (n = 2603) . | All randomized participants (n = 5204) . | ||
|---|---|---|---|---|---|
| . | Participants without post-randomization SARS-CoV-2 Infection (n = 2414) . | Participants with SARS-CoV-2 infection(s) post-randomization (n = 187) . | Participants without post-randomization SARS-CoV-2 infection (n = 2411) . | Participants with SARS-CoV-2 infection(s) post-randomization (n = 192) . | |
| Testosterone | |||||
| Testosterone, ng/dL | 220.3 (47.2) 226.9 (218.4, 222.2) | 224.0 (43.9) 228.5 (217.7, 230.3) | 219.7 (48.1) 225.9 (217.7, 221.6) | 224.6 (48.2) 232.3 (217.7, 231.4) | 220.4 (47.6) 226.8 (219.1, 221.7) |
| Testosterone subgroup | |||||
| Baseline total testosterone levels < 250 ng/dL | 1650 (68.5%) | 125 (66.8%) | 1645 (68.3%) | 126 (65.6%) | 3546 (68.2%) |
| Baseline total testosterone levels ≥ 250 ng/dL | 759 (31.5%) | 62 (33.2%) | 765 (31.7%) | 66 (34.4%) | 1652 (31.8%) |
| DHT | |||||
| DHT, ng/dL | 16.2 (8.0) 15.0 (15.9, 16.7) | 15.6 (7.6) 13.9 (14.4, 16.8) | 16.3 (8.7) 15.1 (15.9, 16.7) | 16.9 (7.9) 15.2 (15.7, 18.1) | 16.2 (8.3) 15.0 (16.0, 16.4) |
| Estradiol | |||||
| Estradiol, pg/mL | 20.9 (8.1) 19.9 (20.6, 21.3) | 21.8 (8.34) 20.7 (20.5, 23.1) | 20.9 (8.4) 19.9 (20.6, 21.3) | 20.9 (7.3) 19.6 (19.8, 22.0) | 21.0 (8.3) 19.9 (20.7, 21.2) |
| . | Testosterone arm (n = 2601) . | Placebo arm (n = 2603) . | All randomized participants (n = 5204) . | ||
|---|---|---|---|---|---|
| . | Participants without post-randomization SARS-CoV-2 Infection (n = 2414) . | Participants with SARS-CoV-2 infection(s) post-randomization (n = 187) . | Participants without post-randomization SARS-CoV-2 infection (n = 2411) . | Participants with SARS-CoV-2 infection(s) post-randomization (n = 192) . | |
| Testosterone | |||||
| Testosterone, ng/dL | 220.3 (47.2) 226.9 (218.4, 222.2) | 224.0 (43.9) 228.5 (217.7, 230.3) | 219.7 (48.1) 225.9 (217.7, 221.6) | 224.6 (48.2) 232.3 (217.7, 231.4) | 220.4 (47.6) 226.8 (219.1, 221.7) |
| Testosterone subgroup | |||||
| Baseline total testosterone levels < 250 ng/dL | 1650 (68.5%) | 125 (66.8%) | 1645 (68.3%) | 126 (65.6%) | 3546 (68.2%) |
| Baseline total testosterone levels ≥ 250 ng/dL | 759 (31.5%) | 62 (33.2%) | 765 (31.7%) | 66 (34.4%) | 1652 (31.8%) |
| DHT | |||||
| DHT, ng/dL | 16.2 (8.0) 15.0 (15.9, 16.7) | 15.6 (7.6) 13.9 (14.4, 16.8) | 16.3 (8.7) 15.1 (15.9, 16.7) | 16.9 (7.9) 15.2 (15.7, 18.1) | 16.2 (8.3) 15.0 (16.0, 16.4) |
| Estradiol | |||||
| Estradiol, pg/mL | 20.9 (8.1) 19.9 (20.6, 21.3) | 21.8 (8.34) 20.7 (20.5, 23.1) | 20.9 (8.4) 19.9 (20.6, 21.3) | 20.9 (7.3) 19.6 (19.8, 22.0) | 21.0 (8.3) 19.9 (20.7, 21.2) |
Values are mean (SD), median (IQR) for continuous, and numbers (%) for categorical data. To convert serum total testosterone concentrations in nanograms per deciliter to nanomoles per liter, multiply testosterone concentration in nanograms per deciliter by 0.0347. To convert estradiol concentrations from picogram per milliliter to picomoles per liter, multiply estradiol concentrations in picogram per milliliter by 3.67. To convert dihydrotestosterone concentrations in nanograms per deciliter to nanomoles per liter, multiply dihydrotestosterone concentrations in nanograms per deciliter by 0.0344.
Abbreviation: DHT, dihydrotestosterone.
Baseline hormone levels in randomized participants with and without COVID-19 and overall
| . | Testosterone arm (n = 2601) . | Placebo arm (n = 2603) . | All randomized participants (n = 5204) . | ||
|---|---|---|---|---|---|
| . | Participants without post-randomization SARS-CoV-2 Infection (n = 2414) . | Participants with SARS-CoV-2 infection(s) post-randomization (n = 187) . | Participants without post-randomization SARS-CoV-2 infection (n = 2411) . | Participants with SARS-CoV-2 infection(s) post-randomization (n = 192) . | |
| Testosterone | |||||
| Testosterone, ng/dL | 220.3 (47.2) 226.9 (218.4, 222.2) | 224.0 (43.9) 228.5 (217.7, 230.3) | 219.7 (48.1) 225.9 (217.7, 221.6) | 224.6 (48.2) 232.3 (217.7, 231.4) | 220.4 (47.6) 226.8 (219.1, 221.7) |
| Testosterone subgroup | |||||
| Baseline total testosterone levels < 250 ng/dL | 1650 (68.5%) | 125 (66.8%) | 1645 (68.3%) | 126 (65.6%) | 3546 (68.2%) |
| Baseline total testosterone levels ≥ 250 ng/dL | 759 (31.5%) | 62 (33.2%) | 765 (31.7%) | 66 (34.4%) | 1652 (31.8%) |
| DHT | |||||
| DHT, ng/dL | 16.2 (8.0) 15.0 (15.9, 16.7) | 15.6 (7.6) 13.9 (14.4, 16.8) | 16.3 (8.7) 15.1 (15.9, 16.7) | 16.9 (7.9) 15.2 (15.7, 18.1) | 16.2 (8.3) 15.0 (16.0, 16.4) |
| Estradiol | |||||
| Estradiol, pg/mL | 20.9 (8.1) 19.9 (20.6, 21.3) | 21.8 (8.34) 20.7 (20.5, 23.1) | 20.9 (8.4) 19.9 (20.6, 21.3) | 20.9 (7.3) 19.6 (19.8, 22.0) | 21.0 (8.3) 19.9 (20.7, 21.2) |
| . | Testosterone arm (n = 2601) . | Placebo arm (n = 2603) . | All randomized participants (n = 5204) . | ||
|---|---|---|---|---|---|
| . | Participants without post-randomization SARS-CoV-2 Infection (n = 2414) . | Participants with SARS-CoV-2 infection(s) post-randomization (n = 187) . | Participants without post-randomization SARS-CoV-2 infection (n = 2411) . | Participants with SARS-CoV-2 infection(s) post-randomization (n = 192) . | |
| Testosterone | |||||
| Testosterone, ng/dL | 220.3 (47.2) 226.9 (218.4, 222.2) | 224.0 (43.9) 228.5 (217.7, 230.3) | 219.7 (48.1) 225.9 (217.7, 221.6) | 224.6 (48.2) 232.3 (217.7, 231.4) | 220.4 (47.6) 226.8 (219.1, 221.7) |
| Testosterone subgroup | |||||
| Baseline total testosterone levels < 250 ng/dL | 1650 (68.5%) | 125 (66.8%) | 1645 (68.3%) | 126 (65.6%) | 3546 (68.2%) |
| Baseline total testosterone levels ≥ 250 ng/dL | 759 (31.5%) | 62 (33.2%) | 765 (31.7%) | 66 (34.4%) | 1652 (31.8%) |
| DHT | |||||
| DHT, ng/dL | 16.2 (8.0) 15.0 (15.9, 16.7) | 15.6 (7.6) 13.9 (14.4, 16.8) | 16.3 (8.7) 15.1 (15.9, 16.7) | 16.9 (7.9) 15.2 (15.7, 18.1) | 16.2 (8.3) 15.0 (16.0, 16.4) |
| Estradiol | |||||
| Estradiol, pg/mL | 20.9 (8.1) 19.9 (20.6, 21.3) | 21.8 (8.34) 20.7 (20.5, 23.1) | 20.9 (8.4) 19.9 (20.6, 21.3) | 20.9 (7.3) 19.6 (19.8, 22.0) | 21.0 (8.3) 19.9 (20.7, 21.2) |
Values are mean (SD), median (IQR) for continuous, and numbers (%) for categorical data. To convert serum total testosterone concentrations in nanograms per deciliter to nanomoles per liter, multiply testosterone concentration in nanograms per deciliter by 0.0347. To convert estradiol concentrations from picogram per milliliter to picomoles per liter, multiply estradiol concentrations in picogram per milliliter by 3.67. To convert dihydrotestosterone concentrations in nanograms per deciliter to nanomoles per liter, multiply dihydrotestosterone concentrations in nanograms per deciliter by 0.0344.
Abbreviation: DHT, dihydrotestosterone.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
